Circulating Biomarkers in Lower Extremity Artery Disease-Reference-Cited by-同舟云学术

Circulating Biomarkers in Lower Extremity Artery Disease

Published:2022-03-23 Issue: Volume:17 Page:
ISSN:1758-3764
Container-title:European Cardiology Review
language:en
Short-container-title:Eur Cardiol

Author:

Ziegler Louise¹^ORCID,Hedin Ulf²^ORCID,Gottsäter Anders³^ORCID

Affiliation:

1. Division of Internal Medicine, Department of Clinical Sciences, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden

2. Vascular Surgery Division, Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden

3. Department of Medicine, Lund University, Malmö, Sweden; Department of Medicine, Skåne University Hospital, Malmö, Sweden

Abstract

Lower extremity artery disease (LEAD), a chronic condition with disturbed lower extremity circulation due to narrowing of the arteries, is predominantly caused by atherosclerosis and is associated with the presence of cardiovascular risk factors and an increased risk of cardiovascular events. LEAD is prevalent among older individuals and predicted to rise with the ageing population. In progressive disease, the patient experiences symptoms of ischaemia when walking and, in advanced critical limb-threatening ischaemia, even at rest. However, LEAD is asymptomatic in most patients, delaying diagnosis and treatment. In this setting, circulating biomarkers may facilitate earlier diagnosis in selected individuals. This review provides a broad overview of the circulating biomarkers investigated to date in relation to LEAD and discusses their usefulness in clinical practice.

Publisher

Radcliffe Media Media Ltd

Subject

Cardiology and Cardiovascular Medicine

Reference128 articles.

1. Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J 2018;39:763–816. https://doi.org/10.1093/eurheartj/ehx095; PMID: 28886620.

2. Frank U, Nikol S, Belch J, et al. ESVM guideline on peripheral arterial disease. Vasa 2019;48(Suppl 102):1–79. https://doi.org/10.1024/0301-1526/a000834; PMID: 31789115.

3. Fowkes FGR, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013;382:1329–40. https://doi.org/10.1016/S0140-6736(13)61249-0; PMID: 23915883.

4. McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 2001;286:1599–606. https://doi.org/10.1001/jama.286.13.1599; PMID: 11585483.

5. Subherwal S, Patel MR, Kober L, et al. Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study. Eur J Prev Cardiol 2015;22:317–25. https://doi.org/10.1177/2047487313519344; PMID: 24398369.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating Soluble EPCR Levels Are Reduced in Patients with Ischemic Peripheral Artery Disease and Associated with Markers of Endothelial and Vascular Function;Biomedicines;2023-09-04

2. Associations of Cardiac Biomarkers With Peripheral Artery Disease and Peripheral Neuropathy in US Adults Without Prevalent Cardiovascular Disease;Arteriosclerosis, Thrombosis, and Vascular Biology;2023-08

3. Peptides associated with hypertensive disorders of pregnancy as possible biomarkers for severity of lower extremity arterial disease;Atherosclerosis;2023-07

4. Present and Future Perspectives on the Role of Biomarkers in Atherosclerotic Cardiovascular Disease Risk Stratification;European Cardiology Review;2023-04-18

5. Role of inflammation in the development of atrial fibrillation;Bulletin of the Russian Military Medical Academy;2023-04-13